Drugs / Ectoine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06170346 | Nov 2022 → Jul 2023 | — | Padjadjaran University | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03186755 | Jun 2017 → Dec 2024 | vernal conjunctivitis | Michael Marchand, MD | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT03932292 Comparator | Dec 2018 → Oct 2019 | stomatitis | Bitop AG | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ectoine | “30 drops of topical antioxidants (Gluconolactone 4%, Hyaluronic acid 0,01%, Allantoin 0,1%, Ferulic acid 3%, Acetyl heptapeptide 0,001%, Silver vine extract 1%, Ectoine 0,01%,...” NCT06170346 ↗ |
| Known as | Ectoin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03932292 ↗ |
| Route | Oral | “rinsed in the mouth for at least 30 seconds” NCT03932292 ↗ |